Estimated Economic Toll of Cognitive Decline in Preclinical Alzheimer’s Disease
Personalized briefing
Discovery of the day · Neurology
Estimated labor market outcomes of people progressing from preclinical to early‐stage Alzheimer’s disease in the United States
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology · Alzheimer’s Disease
Discovery of the day
A new study quantifies the substantial labor market consequences of progressing from preclinical cognitive impairment to early-stage Alzheimer’s disease in the United States, using data from over 20,000 Health and Retirement Study respondents. Researchers found that disease onset was associated with a five-percentage-point reduction in workforce participation, annual earnings losses of $8,233 for men and $5,616 for women, and a 3.5 and 5.6 percentage-point increase in social assistance enrollment for men and women, respectively. For your work on blood-based proteomic biomarkers for Alzheimer’s disease, these findings underscore the critical need for early diagnostic assays that can identify individuals at the preclinical stage, allowing for timely intervention to preserve productivity and reduce the socioeconomic burden of cognitive decline.
Novelty
84%
Rigor
92%
Significance
90%
Validity
91%
Clarity
95%
Advertisement
ScientificChina — The Global Marketplace for Scientific and Medical Equipments Start Browsing →
Your briefing is personalized based on your selected fields, keywords, and research interests.
